CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization

The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immun...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 11; p. 599587
Main Authors Haun, Brien K., Lai, Chih-Yun, Williams, Caitlin A., Wong, Teri Ann S., Lieberman, Michael M., Pessaint, Laurent, Andersen, Hanne, Lehrer, Axel T.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 30.10.2020
Subjects
adjuvant
Adjuvants, Immunologic - administration & dosage
Aluminum Hydroxide - administration & dosage
Aluminum Hydroxide - immunology
Animals
Antibodies, Viral - immunology
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunization
immunogenicity
Immunoglobulin G - immunology
Immunology
Male
Mice
Mice, Inbred BALB C
rapid response
recombinant subunit
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - administration & dosage
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
COVID-19
rapid response
SARS-CoV-2
recombinant subunit
adjuvant
immunogenicity
Online AccessGet full text

Cover

Abstract The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
AbstractList The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralizing antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
Author Lieberman, Michael M.
Lai, Chih-Yun
Pessaint, Laurent
Lehrer, Axel T.
Williams, Caitlin A.
Haun, Brien K.
Wong, Teri Ann S.
Andersen, Hanne
AuthorAffiliation 1 Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii , Honolulu, HI , United States
2 Cell and Molecular Biology Graduate Program, John A. Burns School of Medicine, University of Hawaii , Honolulu, HI , United States
3 BIOQUAL, Inc. , Rockville, MD , United States
AuthorAffiliation_xml – name: 3 BIOQUAL, Inc. , Rockville, MD , United States
– name: 1 Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii , Honolulu, HI , United States
– name: 2 Cell and Molecular Biology Graduate Program, John A. Burns School of Medicine, University of Hawaii , Honolulu, HI , United States
Author_xml – sequence: 1
  givenname: Brien K.
  surname: Haun
  fullname: Haun, Brien K.
– sequence: 2
  givenname: Chih-Yun
  surname: Lai
  fullname: Lai, Chih-Yun
– sequence: 3
  givenname: Caitlin A.
  surname: Williams
  fullname: Williams, Caitlin A.
– sequence: 4
  givenname: Teri Ann S.
  surname: Wong
  fullname: Wong, Teri Ann S.
– sequence: 5
  givenname: Michael M.
  surname: Lieberman
  fullname: Lieberman, Michael M.
– sequence: 6
  givenname: Laurent
  surname: Pessaint
  fullname: Pessaint, Laurent
– sequence: 7
  givenname: Hanne
  surname: Andersen
  fullname: Andersen, Hanne
– sequence: 8
  givenname: Axel T.
  surname: Lehrer
  fullname: Lehrer, Axel T.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33193454$$D View this record in MEDLINE/PubMed
BookMark eNp1kstu1DAUhi1UREvpA7BBWbLJ4Ft82SCNRtCOVAk0M2JrOY5TPCT2EDuVYN0n4dF4EpxJi1okvLF9fP7vt4_PS3Dig7cAvEZwQYiQ71rX9-MCQwwXlZSV4M_AGWKMlgRjevJofQouYtzDPKgkhFQvwCkhSBJa0TPQrcIXbYzztrja_b77VSyb_XirfSo-h2R9cjrZWGxCPcZUrLNjTtzYeAg-5ngKeWNCXzs_SbbLzbbMwBIX24P7ZostmjXup04u-Ffgeau7aC_u53Ow-_hht7oqrz9drlfL69JQVqWyNrXgXCMiuZXI8FoyKaQQVcMZbSS1jELT4Ba2tm5QfjlqUAsZRsxIYSk5B-sZ2wS9V4fB9Xr4oYJ26hgIw43SQ3Kms4rwCmpUEcu4pjVvBYIQM84FliZfBmfW-5l1GOveNiaXZNDdE-jTE---qptwqzhjiAiWAW_vAUP4PtqYVO-isV2nvQ1jVJiyyROKyevNY6-_Jg-_lRP4nGCGEONgW2VcOlY2W7tOIaim1lDH1lBTa6i5NbIS_aN8gP9f8wcMaL0o
CitedBy_id crossref_primary_10_3389_fitd_2022_847598
crossref_primary_10_1016_j_micpath_2021_105108
crossref_primary_10_1080_14760584_2021_1991794
crossref_primary_10_1016_j_mbs_2023_108970
crossref_primary_10_1016_j_cell_2023_04_024
crossref_primary_10_1038_s41541_021_00418_0
crossref_primary_10_1016_j_jvacx_2021_100126
crossref_primary_10_3390_biomedicines10071464
crossref_primary_10_1093_jleuko_qiad106
crossref_primary_10_1128_mBio_01813_21
crossref_primary_10_1016_j_vaccine_2023_12_053
crossref_primary_10_1128_iai_00223_23
crossref_primary_10_3390_vaccines9030296
crossref_primary_10_3390_covid5010002
crossref_primary_10_1038_s41392_022_00996_y
crossref_primary_10_1097_MRM_0000000000000393
crossref_primary_10_3389_fimmu_2022_1086752
crossref_primary_10_1080_14760584_2021_1977630
crossref_primary_10_1016_j_ijbiomac_2021_11_020
crossref_primary_10_3390_immuno4010007
crossref_primary_10_1016_j_ijbiomac_2023_123635
crossref_primary_10_1021_acsinfecdis_1c00600
crossref_primary_10_1111_ijd_15673
crossref_primary_10_1080_09205063_2021_1909412
crossref_primary_10_1371_journal_pone_0257191
Cites_doi 10.1038/s41423-020-0474-z
10.1006/meth.1999.0832
10.4049/jimmunol.181.8.5490
10.1128/jvi.01281-09
10.1126/scitranslmed.abc3539
10.1002/jmv.25748
10.1371/journal.pone.0002260
10.4049/jimmunol.181.1.17
10.1186/1475-2875-10-182
10.1016/j.vaccine.2017.01.068
10.1016/j.intimp.2020.106717
10.1016/s0264-410x(02)00531-5
10.1093/oxfordjournals.aje.a120955
10.1371/journal.pone.0068895
10.1038/s41423-020-0400-4
10.1128/mSphere.00576-17
10.1371/journal.pone.0045851
10.1016/j.it.2020.04.008
10.1016/j.cell.2020.05.015
10.1016/j.vaccine.2005.01.133
10.1016/j.micron.2011.07.012
10.1371/journal.pone.0035421
10.1038/s41541-018-0094-0
10.1016/j.vaccine.2004.07.021
10.3389/fimmu.2018.02464
10.1128/JCM.42.1.65-72.2004
10.1016/j.imlet.2016.07.016
10.1016/j.vaccine.2004.07.050
10.1016/j.celrep.2016.08.065
10.1038/s41577-020-0321-6
10.1101/2020.07.24.220715
10.1016/j.vaccine.2014.02.001
10.1128/JVI.00671-11
10.3390/v6062328
10.1371/journal.pone.0020547
10.1016/j.vaccine.2016.02.063
10.1016/0264-410x(94)90272-0
10.1016/j.cell.2020.02.052
10.1038/d41573-020-00073-5
10.1038/s41598-019-47885-z
10.4049/jimmunol.151.4.2032
10.1080/22221751.2020.1762515
10.1038/s41586-020-2456-9
10.1128/jvi.01505-14
10.1016/j.virol.2005.01.042
10.1007/s12250-018-0009-2
10.1586/erv.11.192
10.1128/jvi.01049-10
10.1371/journal.pntd.0007614
ContentType Journal Article
Copyright Copyright © 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer.
Copyright © 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer
Copyright_xml – notice: Copyright © 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer.
– notice: Copyright © 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2020.599587
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_3750a153e67a4b7f81002677829cc462
PMC7661386
33193454
10_3389_fimmu_2020_599587
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIGMS NIH HHS
  grantid: P30 GM114737
– fundername: NIAID NIH HHS
  grantid: R01 AI132323
– fundername: National Institute of Allergy and Infectious Diseases
  grantid: R01AI132323
– fundername: National Institute of General Medical Sciences
  grantid: P30GM114737
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c465t-bcb877a1397e91c7b96989885d764d94e640cd2f0febd15871d1f06216c98e43
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:31:24 EDT 2025
Thu Aug 21 18:29:02 EDT 2025
Fri Jul 11 04:59:23 EDT 2025
Thu Jan 02 22:57:21 EST 2025
Tue Jul 01 01:32:27 EDT 2025
Thu Apr 24 22:59:10 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
rapid response
SARS-CoV-2
recombinant subunit
adjuvant
immunogenicity
Language English
License Copyright © 2020 Haun, Lai, Williams, Wong, Lieberman, Pessaint, Andersen and Lehrer.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c465t-bcb877a1397e91c7b96989885d764d94e640cd2f0febd15871d1f06216c98e43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Suh-Chin Wu, National Tsing Hua University, Taiwan; Srinivasa Reddy Bonam, Institut National de la Santé et de la Recherche Médicale (INSERM), France
Edited by: Anke Huckriede, University Medical Center Groningen, Netherlands
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
OpenAccessLink https://doaj.org/article/3750a153e67a4b7f81002677829cc462
PMID 33193454
PQID 2461002082
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_3750a153e67a4b7f81002677829cc462
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7661386
proquest_miscellaneous_2461002082
pubmed_primary_33193454
crossref_citationtrail_10_3389_fimmu_2020_599587
crossref_primary_10_3389_fimmu_2020_599587
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-10-30
PublicationDateYYYYMMDD 2020-10-30
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-30
  day: 30
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2020
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Li (B29) 2008; 181
Nkolola (B41) 2014; 32
Tai (B4) 2020; 17
Ma (B25) 2020; 17
(B1) 2020
Robbiani (B39) 2020
Luo (B33) 2018; 33
Zhao (B50) 2010; 84
Hilgers (B15) 1994; 12
Snell (B12) 2016; 16
B31
Mahdi Abdel Hamid (B37) 2011; 6
Hoffmann (B3) 2020; 181
B7
Ng (B48) 2016; 34
Jiang (B24) 2020; 41
Thanh Le (B6) 2020; 19
Harris (B10) 2012; 43
To (B13) 2018; 3
Namekar (B20) 2012; 7
Haun (B53) 2020
Sun (B11) 2003; 21
Morefield (B30) 2005; 23
Gupta (B32) 2020; 86
Wong (B21) 2004; 42
Medina (B35) 2018; 9
Grifoni (B52) 2020; 181
Orr (B14) 2019; 4
Wang (B2) 2020; 92
Blom (B9) 2004; 23
Channappanavar (B51) 2014; 88
Lehrer (B36) 2018; 36
Jaume (B43) 2011; 85
Graham (B45) 1993; 151
Haun (B22) 2019; 13
Ravichandran (B40) 2020; 12
Kumar (B23) 2014; 6
Garcon (B19) 2012; 11
Matsuoka (B27) 2016; 178
Tseng (B34) 2012; 7
Stevens (B8) 2013; 8
Hilgers (B16) 2006
Li (B47) 2008; 181
Sun (B26) 2020; 9
Bisht (B5) 2005; 334
Kim (B46) 1969; 89
Allison (B18) 1999; 19
Iwasaki (B42) 2020; 20
Shah (B17) 2019; 9
Chen (B49) 2010; 84
Yip (B44) 2016; 22
Kusi (B38) 2011; 10
Perrin-Cocon (B28) 2008; 3
32743582 - bioRxiv. 2020 Jul 26
References_xml – volume: 17
  year: 2020
  ident: B25
  article-title: Serum IgA, IgM, and IgG responses in COVID-19
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-020-0474-z
– volume: 19
  start-page: 87
  year: 1999
  ident: B18
  article-title: Squalene and squalane emulsions as adjuvants
  publication-title: Methods
  doi: 10.1006/meth.1999.0832
– volume: 181
  year: 2008
  ident: B47
  article-title: T cell responses to whole SARS coronavirus in humans
  publication-title: J Immunol (Baltimore Md: 1950)
  doi: 10.4049/jimmunol.181.8.5490
– volume: 84
  year: 2010
  ident: B49
  article-title: Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection
  publication-title: J Virol
  doi: 10.1128/jvi.01281-09
– ident: B7
– volume: 12
  year: 2020
  ident: B40
  article-title: Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.abc3539
– volume: 92
  year: 2020
  ident: B2
  article-title: Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures
  publication-title: J Med Virol
  doi: 10.1002/jmv.25748
– volume: 3
  start-page: e2260
  year: 2008
  ident: B28
  article-title: Th1 disabled function in response to TLR4 stimulation of monocyte-derived DC from patients chronically-infected by hepatitis C virus
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0002260
– volume: 181
  start-page: 17
  year: 2008
  ident: B29
  article-title: Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3
  publication-title: J Immunol
  doi: 10.4049/jimmunol.181.1.17
– volume: 10
  year: 2011
  ident: B38
  article-title: Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques
  publication-title: Malar J
  doi: 10.1186/1475-2875-10-182
– ident: B31
– volume: 36
  year: 2018
  ident: B36
  article-title: Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2017.01.068
– start-page: 155
  volume-title: Coronavirus disease (COVID-19) - Weekly Epidemiological Update
  year: 2020
  ident: B1
– volume: 86
  year: 2020
  ident: B32
  article-title: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.106717
– volume: 21
  year: 2003
  ident: B11
  article-title: Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro
  publication-title: Vaccine
  doi: 10.1016/s0264-410x(02)00531-5
– volume: 89
  year: 1969
  ident: B46
  article-title: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a120955
– volume: 8
  start-page: e68895
  year: 2013
  ident: B8
  article-title: An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT is functionally superior to Freund’s adjuvant
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0068895
– volume: 17
  year: 2020
  ident: B4
  article-title: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-020-0400-4
– volume: 3
  year: 2018
  ident: B13
  article-title: Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice
  publication-title: mSphere
  doi: 10.1128/mSphere.00576-17
– volume: 7
  start-page: e45851
  year: 2012
  ident: B20
  article-title: Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0045851
– volume: 41
  start-page: 545
  year: 2020
  ident: B24
  article-title: Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020)
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2020.04.008
– volume: 181
  start-page: 1489
  year: 2020
  ident: B52
  article-title: Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
– start-page: S2
  year: 2006
  ident: B16
  article-title: Sucrose fatty acid sulphate esters as novel vaccine adjuvant
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.01.133
– volume: 43
  start-page: 192
  year: 2012
  ident: B10
  article-title: Alhydrogel(R) adjuvant, ultrasonic dispersion and protein binding: a TEM and analytical study
  publication-title: Micron
  doi: 10.1016/j.micron.2011.07.012
– volume: 22
  start-page: 25
  year: 2016
  ident: B44
  article-title: Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS
  publication-title: Hong Kong Med J
– volume: 7
  start-page: e35421
  year: 2012
  ident: B34
  article-title: Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0035421
– volume: 4
  start-page: 1
  year: 2019
  ident: B14
  article-title: Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-018-0094-0
– volume: 23
  year: 2004
  ident: B9
  article-title: Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2004.07.021
– volume: 9
  year: 2018
  ident: B35
  article-title: A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.02464
– volume: 42
  start-page: 65
  year: 2004
  ident: B21
  article-title: Detection of human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere immunoassay
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.42.1.65-72.2004
– volume: 178
  year: 2016
  ident: B27
  article-title: Requirement of TLR4 signaling for the induction of a Th1 immune response elicited by oligomannose-coated liposomes
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2016.07.016
– volume: 23
  year: 2005
  ident: B30
  article-title: Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2004.07.050
– volume: 16
  year: 2016
  ident: B12
  article-title: Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T Cells and Control Persistent Virus Infection
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.08.065
– volume: 20
  year: 2020
  ident: B42
  article-title: The potential danger of suboptimal antibody responses in COVID-19
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0321-6
– year: 2020
  ident: B53
  article-title: CoVaccine HT adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation
  publication-title: bioRxiv
  doi: 10.1101/2020.07.24.220715
– volume: 32
  year: 2014
  ident: B41
  article-title: Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2014.02.001
– volume: 85
  year: 2011
  ident: B43
  article-title: Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway
  publication-title: J Virol
  doi: 10.1128/JVI.00671-11
– volume: 6
  year: 2014
  ident: B23
  article-title: Infection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strain
  publication-title: Viruses
  doi: 10.3390/v6062328
– volume: 6
  start-page: e20547
  year: 2011
  ident: B37
  article-title: Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020547
– volume: 34
  year: 2016
  ident: B48
  article-title: Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.02.063
– volume: 12
  year: 1994
  ident: B15
  article-title: A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals
  publication-title: Vaccine
  doi: 10.1016/0264-410x(94)90272-0
– volume: 181
  year: 2020
  ident: B3
  article-title: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 19
  year: 2020
  ident: B6
  article-title: The COVID-19 vaccine development landscape
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/d41573-020-00073-5
– volume: 9
  start-page: 11520
  year: 2019
  ident: B17
  article-title: The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-47885-z
– volume: 151
  year: 1993
  ident: B45
  article-title: Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus
  publication-title: J Immunol
  doi: 10.4049/jimmunol.151.4.2032
– volume: 9
  year: 2020
  ident: B26
  article-title: Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
  publication-title: Emerg Microbes Infect
  doi: 10.1080/22221751.2020.1762515
– year: 2020
  ident: B39
  article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals
  publication-title: Nature
  doi: 10.1038/s41586-020-2456-9
– volume: 88
  year: 2014
  ident: B51
  article-title: Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection
  publication-title: J Virol
  doi: 10.1128/jvi.01505-14
– volume: 334
  year: 2005
  ident: B5
  article-title: Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein
  publication-title: Virology
  doi: 10.1016/j.virol.2005.01.042
– volume: 33
  year: 2018
  ident: B33
  article-title: Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine
  publication-title: Virol Sin
  doi: 10.1007/s12250-018-0009-2
– volume: 11
  year: 2012
  ident: B19
  article-title: Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion
  publication-title: Expert Rev Vaccines
  doi: 10.1586/erv.11.192
– volume: 84
  year: 2010
  ident: B50
  article-title: T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice
  publication-title: J Virol
  doi: 10.1128/jvi.01049-10
– volume: 13
  start-page: e0007614
  year: 2019
  ident: B22
  article-title: Serological evidence of Ebola virus exposure in dogs from affected communities in Liberia: A preliminary report
  publication-title: PLoS Neglected Trop Dis
  doi: 10.1371/journal.pntd.0007614
– reference: 32743582 - bioRxiv. 2020 Jul 26;:
SSID ssj0000493335
Score 2.3844862
Snippet The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 599587
SubjectTerms adjuvant
Adjuvants, Immunologic - administration & dosage
Aluminum Hydroxide - administration & dosage
Aluminum Hydroxide - immunology
Animals
Antibodies, Viral - immunology
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunization
immunogenicity
Immunoglobulin G - immunology
Immunology
Male
Mice
Mice, Inbred BALB C
rapid response
recombinant subunit
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - administration & dosage
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQpUpcEJTX8qiMxAnJNIkdOzkuVasFCYR2F9SbFb_Ett2kosmBO7-En8YvYcZOV7sIwYVrMk6smbHnG3n8DSEvg3ES4ohkprCCCSc5M7kKLMgiD9wUThi8O_z-g5x9Eu_OyrOtVl9YE5bogZPijjiEtAaWpZeqEUaFCjlDkfWsqK0VafeFmLeVTJ0n3Ms5L9MxJmRh9VFYrdcD5INF9ho5trCEbisQRb7-P4HM32slt4LP6V1yZ0SNdJpme4_c8u0B2U99JL_dJ5fH3efG4hE5nS1_fv9Bp-58AIjc049dj-VACCjpvDPDdU_f4o0QT-epOBae9x3FJHRtYlEMXUznCwYfZAVdXK0uPF3kacx4Y_MBWZ6eLI9nbGyjwEA_Zc-MNZVSDUI9X-dWmTo2jaxKp6RwtfBSZNYVIQveuBw0k7s8ZGAraevKC_6Q7LVd6x8T6svABcg4LyFr47KpYEfIvCkrW1mr6gnJblSq7Ugxjp0uLjWkGmgFHa2g0Qo6WWFCXm2GXCV-jb8Jv0E7bQSRGjs-AIfRo8PofznMhLy4sbKGpYTnI03ru-FaI7VebFoKMo-S1Te_4rBVcVGKCVE7_rAzl9037epLpOtWAIF4JZ_8j8k_JbdRHzF4Zs_IXv918M8BFfXmMC6AX3e2CYo
  priority: 102
  providerName: Directory of Open Access Journals
Title CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization
URI https://www.ncbi.nlm.nih.gov/pubmed/33193454
https://www.proquest.com/docview/2461002082
https://pubmed.ncbi.nlm.nih.gov/PMC7661386
https://doaj.org/article/3750a153e67a4b7f81002677829cc462
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELfGEGgviP8UxmQknpAyktixkwc0lYlRkIZQ26G-RfE_6GiT0SYSe-eT7KPtk3DnpBVFhZc8OLaT3J19v4vt3xHy0ikjwI-IQMWaB9wIFqhIusCJOHJMxYYrPDt8-kkMzvjHSTLZIav0Vp0Al1tDO8wndbaYHf78cXkEA_4NRpzgb1-76XzeQKgXh4dIn5XKG-QmOCaJ4_S0Q_vnLRhmjCXt2ub2lnvkNgOjZDzhG47K8_lvA6F_76X8wzmd3CV3OlRJ-60Z3CM7trxPbrV5Ji8fkNlx9aXQuIROB-PrX1e0b84bgNA1_VzVuF0IAScdVqpZ1vQDnhixdNhunoXyuqIYpM6V3zRDR_3hKIAOg5iOLqbfLR1FbZvuROdDMj55Nz4eBF2ahUBzkdSB0iqVskAoaLNIS5X5pJJpYqTgJuNW8FCb2IXOKhOBkCITuRB0KXSWWs4ekd2yKu0TQm3iGIc6xgqI6pgoUpgxQquSVKday6xHwpVIc91RkGMmjFkOoQgqJPcKyVEheauQHnm1bnLR8m_8r_Jb1NO6IlJn-4Jq8TXvRmLOACMVMM9bIQuupEuRhBZp9OJMg0DiHnmx0nIOQw3XT4rSVs0yR-o9n9QU6jxutb5-1MpqekRu2MPGu2zeKaffPJ23BIjEUvH0n30-I3v4kd5jhvtkt1409jlAoVod-F8IcH0_iQ68sf8G1Q8Iew
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CoVaccine+HT%E2%84%A2+Adjuvant+Potentiates+Robust+Immune+Responses+to+Recombinant+SARS-CoV-2+Spike+S1+Immunization&rft.jtitle=Frontiers+in+immunology&rft.au=Haun%2C+Brien+K&rft.au=Lai%2C+Chih-Yun&rft.au=Williams%2C+Caitlin+A&rft.au=Wong%2C+Teri+Ann+S&rft.date=2020-10-30&rft.eissn=1664-3224&rft.volume=11&rft.spage=599587&rft_id=info:doi/10.3389%2Ffimmu.2020.599587&rft_id=info%3Apmid%2F33193454&rft.externalDocID=33193454
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon